BioSpace News Archive

Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”) today announced that the French Agency for Food, Environmental and Occupational Health and Safety (ANSES) and the Belgian Federal Agency for Medicines and Health Products (FAMHP) have cleared the amended protocol of the Company’s Phase II trial evaluating Allocetra™ in patients with sepsis.

Nuvectis Pharma, Inc. (NASDAQ: NVCT) (“Nuvectis” or the “Company”) today announced a collaboration with the European Network of Gynecological Oncology Trial Groups (“ENGOT”) and the GOG Foundation, Inc. (“GOG-F”) to conduct the NXP800 Phase 1b clinical trial in ARID1A-mutated, ovarian clear cell and endometroid carcinomas in Europe and the United States.

Aktis Oncology, a biotechnology company discovering and developing novel classes of targeted alpha radiopharmaceuticals to treat a broad range of solid tumors, announced the company will present at the upcoming 41st Annual J.P. Morgan Healthcare Conference, taking place in San Francisco, CA, Jan. 9 – 12.

Juno Pharmaceuticals Canada (“Juno”), a Canadian specialty pharmaceutical company, announced that it has received approval from Health Canada to import Amoxicillin powder for oral suspension (“Amoxicillin”) pursuant to Health Canada’s exceptional importation and sale guidelines.

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management will present at the 41st Annual J.P. Morgan Healthcare Conference on Monday, January 9, 2023 at 11:15 a.m. ET/8:15 a.m. PT.

Ventus Therapeutics, Inc. announced today the nomination of a potential first-in-class cGAS inhibitor, VENT-03, as the company’s first development candidate directed against cGAS.

bioAffinity Technologies, Inc . (NASDAQ: BIAF; BIAFW) announced today that the U.S. Patent and Trademark Office (USPTO) has provided a Notice of Allowance for a patent application titled “ Porphyrin Compounds and Compositions Useful for Treating Cancer ” for the targeted delivery of novel cancer treatments.

Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), Dr. David Young, Processa Pharmaceuticals, CEO will present an update on Processa’s future therapeutic focus and strategy at the upcoming Biotech Showcase on January 11, 2023, at 10 am.

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Jean-Jacques Bienaimé , Chairman and Chief Executive Officer, will present at the 41st Annual J.P. Morgan Healthcare Conference on Monday, January 9, 2023, at 10:30 am PT / 1:30 pm ET , in San Francisco, California.

Edgewise Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference on January 10, 2023.